Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Fiasp (insulin aspart) for the Treatment of Type 1 and Type 2 Diabetes

Drug (Brand/Generic)

Fiasp/insulin aspart

Developer

Novo Nordisk

Product Description

Fast-acting insulin analogue

Current Indication

Type 1 and Type 2 diabetes

Market Sector

Diabetes

Development Status

Approved in the US, Canada, Norway, Iceland, and Europe
Expand
Close
Close
Close

Go Top